Cevimeline hydrochloride (1, Fig. 1), chemically known as cis-2-methylspiro(1,3-oxathiolane- 5,3)quinuclidine, exists as a racemic mixture, an oral muscarinic agent that has been recently approved for the treatment of xerostomia in the setting of Sjogren's syndrome. 1 Sjogren's syndrome is a systemic chronic inflammatory disorder characterized by xerostomia, anhidrosis, and conjunctivitis sicca due to lymphocytic infiltration of exocrine organs, such as salivary, sweat, and ...